Hyperion DeFi Files 8-K for Material Agreement

Ticker: HYPD · Form: 8-K · Filed: Sep 24, 2025 · CIK: 1682639

Hyperion Defi, INC. 8-K Filing Summary
FieldDetail
CompanyHyperion Defi, INC. (HYPD)
Form Type8-K
Filed DateSep 24, 2025
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001, $50 million, $100 million, $29.0 m
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, corporate-action

TL;DR

Hyperion DeFi (fka Eyenovia) filed an 8-K for a material definitive agreement - check for details.

AI Summary

On September 24, 2025, Hyperion DeFi, Inc. (formerly Eyenovia, Inc.) filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Laguna Hills, California.

Why It Matters

This 8-K filing signals a significant development for Hyperion DeFi, Inc., potentially involving a new contract or partnership that could impact its business operations and financial standing.

Risk Assessment

Risk Level: medium — An 8-K filing regarding a material definitive agreement indicates a significant event, but the specific nature and impact of the agreement are not detailed in this summary.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Hyperion DeFi, Inc.?

The filing indicates an entry into a material definitive agreement, but the specific details of the agreement are not provided in the summary information.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on September 24, 2025.

What was Hyperion DeFi, Inc. formerly known as?

Hyperion DeFi, Inc. was formerly known as Eyenovia, Inc.

Where are Hyperion DeFi, Inc.'s principal executive offices located?

The principal executive offices are located at 23461 South Pointe Drive, Suite 390, Laguna Hills, CA 92653.

What is the SIC code for Hyperion DeFi, Inc.?

The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 734 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2025-09-24 07:14:07

Key Financial Figures

Filing Documents

01. Entry into a Material Definitive

Item 1.01. Entry into a Material Definitive Agreement. On September 24, 2025, Hyperion DeFi, Inc. (the "Company") entered into Amendment No. 1 (the "Amendment") to the Amended and Restated Sales Agreement (the "A&R Sales Agreement") with Chardan Capital Markets, LLC, with respect to the Company's existing at-the-market offering program. The Amendment, among other things, increases the aggregate offering price under the A&R Sales Agreement from $50 million to $100 million. The issuance and sale of shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), by the Company under the A&R Sales Agreement have been, and the future issuance and sale of shares, if any, will be, pursuant to the Company's Registration Statement on Form S-3 (File No. 333-282458) filed with the U.S. Securities and Exchange Commission (the "SEC") on October 1, 2024 (the "Registration from time to time. As of September 24, 2025, the Company has offered and sold 4,176,196 shares of Common Stock pursuant to the A&R Sales Agreement for net proceeds of approximately $29.0 million, after deducting commissions and offering expenses. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment, a copy of which is incorporated herein by reference as Exhibit 1.1. The legal opinion of Covington & Burling LLP relating to the additional shares of Common Stock that may be sold under the Company's at-the-market offering program is filed herewith as Exhibit 5.1. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Common Stock discussed herein, nor shall there be any offer, solicitation, or sale of the Common Stock in any state in which such offer, solicitation or sale would be unlawful p

01. Exhibits

Item 9.01. Exhibits. (d) Exhibits Exhibit No. Description 1.1 Amendment No. 1 to Amended and Restated Sales Agreement, dated September 24, 2025, by and between Hyperion DeFi, Inc. and Chardan Capital Markets, LLC. 5.1 Opinion of Covington & Burling LLP. 23.1 Consent of Covington & Burling LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HYPERION DEFI, INC. Date: September 24, 2025 /s/ Hyunsu Jung Hyunsu Jung Interim Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing